Industry Reports Services Press Release
  •   Blogs
  • Contact us About us

    Asia Pacific Contract Research Organization (CRO) Market Forecast 2028 By End-use (Pharmaceutical & Biopharmaceutical Companies, Medical Device Companies, Academic Institutes), By Therapeutic Area (Oncology, Clinical Pharmacology, Cardiology, Infectious Disease, Neurology, Gastroenterology & Hepatology, Ophthalmology), By Service Type (Early Phase Development Services {Discovery Services, Chemistry, Manufacturing & Control (CMC), Pre-clinical Services [Pharmacokinetics/Pharmacodynamics (PK/PD), Toxicology Testing Services]}, Clinical Research Services {Phase I, Phase II, Phase III, Phase IV}, Laboratory Services {Bioanalytical Testing Services, Analytical Testing Services [Physical Characterization, Raw Material Testing, Batch Release Testing, Stability Testing]}, Consulting Services), Research Report, Country Outlook (Japan, India, China, Australia, South Korea, Thailand, New Zealand, Singapore, Malaysia), Price Trends, Historic Data, Growth Prospects, Competitive Industry Share
    Published Date: March 2022   |   Report ID: GR2091   |   Delivery: PDF  Request Free Sample

    Asia Pacific Contract Research Organization Market size crossed USD 9,408.9 million in 2021 and is projected to observe over 7.9% growth rate from 2022 to 2028. Rising collaboration along with increasing focus of pharmaceutical companies on novel drug development for treatment of various chronic disease is the major factor propelling the market demand.

    Contract research organizations (CROs) also known as clinical research organization, assist in the research, development, and commercialization of new products for sponsor companies, primarily in the pharmaceutical, biotechnology, and medical device industries. They offer services such as preclinical research, clinical research, clinical trial management, commercialization, and pharmacovigilance among others.


    Asia Pacific Contract Research Organization Market

    Get more details on this report - Request Free Sample PDF

    Increasing number of clinical trials being conducted in Asia Pacific region especially in countries such as Thailand, South Korea, and Singapore among others is the major factor driving regional market growth. Also, with an easy access to resources, significantly large patient pool as well as high-cost savings, Asia Pacific represents a significant opportunity in the CRO marketplace over the coming years. Moreover, as governments simplify the regulatory framework and countries in Asia offer competitive healthcare infrastructure to perform clinical trials, several sponsors are noted to lay significant emphasis on the region.

    Asia Pacific Market, By Service Type

    The clinical research services segment revenue was over USD 5,312.3 million in 2021, owing to presence and constant support of government bodies such as Human Studies Review Committee (HSRC) or Institutional Review Board (IRB) supervises. These government bodies are responsible for commands professionalism and reviews in clinical research for ensuing patient safety in the process. In addition, necessity to setup sustainable clinical research centers with operational in agreement to international standards for appropriate assessment of novel products is further expected to upsurge the industry growth.

    Asia Pacific Market, By Therapeutic Area

    The oncology segment held more than 53.9% Asia Pacific market share in 2021, due to growing incidences of cancer ultimately increases the new drug development and clinical trial activities for disease treatment. Moreover, rise in the number of oncology CRO services in the region is another contributing factor in the segment growth.

    Asia Pacific Market, By End-use

    The pharmaceutical & biopharmaceutical companies’ segment will surpass USD 8,992.3 million revenue by end of 2028, attributed to increasing prevalence of various chronic diseases such as cancer, cardiac disease, neurological, infectious disease and kidney disorders. Also, increasing R&D investment from pharma & biopharma companies in development of novel drugs along with rising shifts of clinical trials from developed countries to Southeast Asia countries will upsurge the demand for Asia Pacific CRO services.

    Asia Pacific Market, By Country

    China contract research organization (CRO) market will witness 8.8% CAGR to reach USD 4,363.4 million revenue by 2028. Huge patient population, emergence of severe diseases along with introduction of new laboratories in the country are few of the country level growth driving factors. For instance, in October 2020, PPD is opening a new laboratory in Suzhou, China, to support China-based biotech companies and Western pharmaceutical companies managing China research studies. The laboratory will offer bioanalytical, biomarker and vaccine services to support trials across all phases of pharmaceutical development. Similarly, rise in number of infectious diseases including COVID-19 cases are attracting CROs to conduct trials to fast-track procedures and take advantage of the large patient pool.

    Competitive Industry Landscape

    Major players involved in the market include Charles River Laboratories, IQVIA, PPD, LLC, ICON plc, Syneos Health and WuXi AppTec.

    Companies undertake various strategies such as new product launch, mergers, acquisitions, collaborations, geographic expansions to strengthen their market position. For instance, in December 2021, CMIC and Lokavant, a leading clinical trial intelligence company announced their enterprise partnership. This agreement aimed to expand Lokavant’s clinical trial intelligence platform in the Asia-Pacific region. This partnership strategy is expected to enhance their business relation as well as help Lokavant in strengthening its market position in untapped economies of Asia Pacific region.

    Frequently Asked Question(FAQ) :

    What is the Asia Pacific CRO market worth?
    The industry size for contract research organization (CRO) in Asia Pacific was accounted for USD 9,408.9 million in 2021 and will witness a 7.9% growth rate through 2028 owing to the surging focus of pharma firms on novel drug development.
    What are contract research organizations?
    Contract research organizations or clinical research organizations help in the research, development, and commercialization of novel products for sponsor companies, including pharmaceutical, biotechnology, and medical device industries.
    How are pharmaceutical & biopharmaceutical companies driving the contract research organization industry growth in APAC?
    The market share for CRO in Asia Pacific from pharmaceutical & biopharmaceutical companies is set to exceed USD 8,992.3 million by 2028, driven by the higher burden of various chronic diseases, including cancer, cardiac, neurological, infectious and kidney disorders.
    Why is the demand for contract research organizations growing in China?
    The market revenue for CRO in China is expected to generate over USD 4,363.4 million revenue by 2028 owing to the expanding patient population and the influx of severe diseases in the country.

    Get this research report on Asia Pacific Contract Research Organization (CRO) Market customized according to your business requirements.

    report-purchase - logo Buy Now

    Why Choose us?

    • on-time delivery On-Time Delivery

      We commit to on-time delivery of reports to keep you ahead.

    • assured quality Assured Quility

      With a wide network of industry experts and trained in-house analysts, we assure best service quality.

    • Custom Research Service

      We offer research services to meet specific client requirements and provide them with actionable insights on target markets.

    • payment security Payment Security

      Our safe payment gateway gives you full control of your personal data, at all times.

    Connect with our sales team


     [email protected]